Under the agreement, Dako will develop a diagnostic test for Amgen’s cancer drug candidate, which is in clinical development.

Dako CEO Lars Holmkvist said they are pleased to be selected as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies.

"This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist said.

Dako and Amgen partnered to develop a drug and diagnostics for a rare but deadly cancer in January 2012.